[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634085":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":11,"centralContacts":35,"locations":41,"responsibleParty":59,"collaborators":11,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":11,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":11,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":11,"overallStatus":44,"whyStopped":11,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Beijing InnoCare Pharma Tech Co., Ltd.","INDUSTRY",[8,14,17,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Single ascending doses of ICP-538 tablet","EXPERIMENTAL",null,[13],"Drug: ICP-538 Tablets",{"label":15,"type":10,"description":11,"interventionNames":16},"Multiple ascending doses of ICP-538 tablet",[13],{"label":18,"type":19,"description":11,"interventionNames":20},"Single ascending doses of placebo","PLACEBO_COMPARATOR",[21],"Drug: ICP-538 placebo Tablets",{"label":23,"type":19,"description":11,"interventionNames":24},"Multiple ascending doses of placebo",[21],[26,31],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"DRUG","ICP-538 Tablets","ICP-538 will be administered as tablet",[15,9],{"type":27,"name":32,"description":33,"armGroupLabels":34,"otherNames":11},"ICP-538 placebo Tablets","Matching placebo will be administered as tablet",[23,18],[36],{"name":37,"role":38,"phone":39,"phoneExt":11,"email":40},"Quankun Zhuang","CONTACT","+86-13011825339","zhuangqk@gobroadhealthcare.com",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Beijing Gobroad Hospital","RECRUITING","Beijing","Beijing Municipality","102200","China","CN",{"type":51,"coordinates":52},"Point",[53,54],116.39723,39.9075,{"lat":54,"lon":53},[57],{"name":58,"role":38,"phone":11,"phoneExt":11,"email":11},"Xiaohua Tian",{"type":60,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100634085","phase-1-study-of-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-icp-538-in-healthy-subjects-100634085",false,"NCT07535099","Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects","A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ICP-538 in Healthy Participants","Inclusion Criteria:\n\n1. Voluntarily sign the ICF..\n2. BMI between 18-26 kg\u002Fm² (inclusive). Male weight ≥50 kg; female weight ≥45 kg.\n3. Vital signs, physical examination, ECG, Chest X-ray, Abdominal ultrasound results at screening are within normal range or showing minor deviations deemed not clinically significant by the investigator.\n4. Laboratory test results at screening and baseline are within the normal reference range.\n5. Reproductive Status：Females of non-childbearing potential . Male participants and their partners must agree to use effective contraception throughout the study and for 3 months after the last dose. Male participants must not donate sperm during this period.\n\nExclusion Criteria:\n\n1. Evidence or history of clinically significant diseases, or Evidence or history of allergic diseases .\n2. Clinically significant gastrointestinal dysfunction that may affect drug intake, transport, or absorption.\n3. Acute illness within 14 days before dosing.\n4. Severe infection within 6 months before dosing, or chronic\u002Frecurrent infections.\n5. Participant and\u002For first-degree relative with hereditary immunodeficiency.\n6. Major trauma or surgery within 3 months before dosing.\n7. History of active\u002Flatent TB or contact with an open TB case within 6 months before dosing.\n8. Positive urine drug screen.\n9. Alcohol abuse.\n10. Use of tobacco\u002Fnicotine products within 3 months before the first dose.\n11. Use of any prescription\u002Fnon-prescription drugs, herbal medicines, supplements within 14 days before first dose; or systemic corticosteroids, immunosuppressants\u002Fmodulators, hormone replacement therapy within 30 days before first dose; or any other factor affecting drug absorption, distribution, metabolism, and excretion.\n12. Consumption of caffeine-containing foods\u002Fbeverages within 48 hours before the first dose.\n13. Use of known CYP3A4 inducers\u002Finhibitors within 14 days or 5 half-lives (whichever is longer) before the first dose.\n14. Dieting, dietary therapy within 30 days before the first dose.\n15. Positive for syphilis antibody, HCV-Ab, HBsAg, HBcAb, or HIV-Ab at screening.\n16. Administration of live vaccines within 6 weeks before the first dose or planned during study or within 8 weeks after study.",true,"ALL","18 Years","50 Years",{"count":73,"type":74},104,"ESTIMATED","INTERVENTIONAL",[77],"PHASE1","This is a Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects",[80],"Health Services Research","2026-06-16",{"date":83,"type":84},"2026-06-18","ACTUAL",{"date":86,"type":84},"2026-03-13",{"date":88,"type":74},"2026-09",{"name":5,"class":6},1]